Astex Pharmaceuticals Announces Presentations at Upcoming Conferences

DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that James S.J. Manuso, PhD, chairman and chief executive officer, will present at the following conferences:

  • BIO CEO & Investor Conference in New York on February 14th at 11:30 am ET
  • Citi Global Health Care Conference in New York on February 29th at 11:30 am ET

Live webcasts will be available in the Investor Events section of the Company's website, www.astx.com. The webcasts will be archived for 30 days.

In addition, Mohammad Azab, MD, chief medical officer, will be a panelist in the BIO CEO & Investor Conference Therapeutic Workshop, “Secrets of Oncology Success – Lessons and Trends in Phase II Clinical Trial Outcomes” on February 13th at 10:30 am ET in New York.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.



CONTACT:

Astex Pharmaceuticals, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Marketing
[email protected]
Susanna Chau, 925-560-2845
Manager
Investor Relations
[email protected]
or
The Trout Group
Alan Roemer, 646-378-2945
Managing Director
[email protected]
or
College Hill
Melanie Toyne-Sewell (Europe), +44 20 7866 7866
Rebecca Skye Dietrich (US), 857-241-0795
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.